XNCR
Xencor Inc Health Care Pharmaceutical Preparations Russell 3000
$29.82Close
$2.1BMarket cap
$10.41 – $29.9952-week range
Nov 4, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 98 · stronger than 98% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high 1% below its 52-week high
Cautions
- Past its pivot 13.2% above its $26.35 pivot
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
1%
1wk
up 18.4%
price change
1mo
up 19.5%
price change
12-month return
up 111%
market up 11% ·
its own up 92%
F-score
—
— Not assessed
Altman Z
4.25
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.4×
price / book
Earnings yield
down 8.2%
EBIT / enterprise value
Cheaper than
23%
of the market · expensive
Revenue growth
up 14%
year on year
EPS growth
—
latest quarter
Sales growth
up 17%
latest quarter · +104 pts
ROE
down 14%
return on equity
Free cash margin
down 110%
-$138.3M FCF
D/E
0.12
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Long-term debt down 34% ($0.1B → $0.1B)
- Revenue reaccelerating (-37% then +14%)
Trade setup
ATR%
6.1%
$1.82 a day · 2×ATR $26.17
RS
98 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.41
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Contractions
2
24% → 17%
Pivot
$26.35
13.2% above
Volume dry-up
1.4×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.3% over the year, from 70m to 72m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 26, 2026
Results reaction
Oct 26, 2026+18% vs market2 sessions after results
Financials
- Net -73%
- Free cash -110%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $122.7M | $275.1M | $164.6M | $174.6M | $110.5M | $125.6M |
| Operating income | -$76.8M | $43.8M | -$82.5M | -$132.4M | -$178.4M | -$177.5M |
| Net income | -$69.3M | $82.6M | -$55.2M | -$133.1M | -$232.6M | -$91.9M |
| Net margin | -57% | 30% | -34% | -76% | -211% | -73% |
| Earnings per share | -$1.21 | $1.37 | -$0.93 | -$2.20 | -$3.58 | -$1.24 |
| Free cash flow | -$15.5M | -$30.2M | -$14.0M | -$96.4M | -$208.3M | -$138.3M |
| Free cash margin | -13% | -11% | -9% | -55% | -189% | -110% |
| Cash | $163.5M | $143.5M | $53.9M | $53.8M | $40.9M | $54.1M |
| Long-term debt | — | — | $0 | $161.8M | $115.2M | $76.5M |
| Shareholders' equity | $572.4M | $733.5M | $727.5M | $661.8M | $677.6M | $635.6M |
| Shares outstanding | 57.87m | 59.36m | 60m | 61m | 70.26m | 71.87m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 26, 2026 | Results · Regulation FD · Other events ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 29, 2026 | Material agreement · Results · Regulation FD ↗ |
| Jun 18, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| May 5, 2026 | Regulation FD ↗ |
| Apr 27, 2026 | Director or officer change ↗ |
| Mar 9, 2026 | Agreement ended ↗ |
| Mar 4, 2026 | Regulation FD ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 8, 2026 | Results ↗ |
| Nov 5, 2025 | Results ↗ |